Buscar en
Revista Colombiana de Reumatología (English Edition)
Toda la web
Inicio Revista Colombiana de Reumatología (English Edition)
Journal Information
Share
Share
Download PDF
More article options
ePub
Visits
...
Original Investigation
DOI: 10.1016/j.rcreue.2017.09.006
Effects of belimumab in Colombian patients with systemic lupus erythematosus; a prospective observational study
Efectos del belimumab en pacientes colombianos con lupus eritematoso sistémico, un estudio prospectivo observacional
Visits
...
Alex Echeverria, Iván Posso-Osorioa, Christian Figueroaa,b, Juan-Pablo Susoa, Andrés Hormazaa, Fabio Bonilla-Abadíaa, Andrés Agualimpiaa, Carlos A. Cañasa, Gabriel J. Tobóna,c,
Corresponding author
gtobon1@yahoo.com

Corresponding author.
a GIRAT (Grupo de investigación en Reumatología, Autoinmunidad y Medicina traslacional), Fundación Valle del Lili y Universidad Icesi, Cali, Colombia
b Departamento de urgencias, Fundación Valle del Lili, Cali, Colombia
c Laboratorio de Inmunología, Fundación Valle del Lili, Cali, Colombia
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Patient's follow-up.
Table 2. Prior and concomitant drugs along with belimumab therapy.
Show moreShow less
Abstract
Introduction

Belimumab, a monoclonal type Ig G1 antibody that binds and inhibits the soluble form of the Blys (B lymphocyte stimulator) has shown to be effective in the management of systemic lupus erythematosus (SLE). However, its effectiveness is unknown in an ethnically variable population, such as in Colombia.

Methods

A prospective observational study was conducted between February 2015 and February 2016 on patients with active SLE disease despite being on standard treatment and who were treated with Belimumab.

Results

Belimumab showed a significant improvement in joint, cutaneous and hematological involvement, with an increase in complement levels, a decrease in lupus crises and hospital admissions. After 3 months there was lower activity, calculated by SLEDAI, with stability for 9 months.

Conclusions

In a real-life patient setting, it was observed that belimumab was useful in Colombian patients with SLE and refractory to standard therapy, especially in the joint, hematological, and cutaneous manifestations.

Keywords:
Belimumab
Systemic lupus erythematosus
Colombian patients
Resumen
Introducción

El belimumab es un anticuerpo monoclonal tipo IgG1 que se une e inhibe la forma soluble de Blys (estimulador de linfocitos B) y ha mostrado efectividad en el manejo del lupus eritematoso sistémico (LES). Sin embargo, se desconoce su efectividad en una población tan variable étnicamente como la colombiana.

Métodos

Se realizó un estudio prospectivo observacional entre febrero de 2015 y febrero de 2016, en pacientes con LES, con enfermedad activa a pesar del tratamiento estándar, quienes fueron tratados con belimumab.

Resultados

El uso de belimumab se relacionó con una mejoría significativa en los compromisos articular, cutáneo y hematológico, con aumento de los niveles de complemento, disminución de las exacerbaciones por LES y de las hospitalizaciones, además de una menor actividad calculada por SLEDAI después de 3 meses de utilización y con una estabilidad mantenida hasta los 9 meses.

Conclusiones

Se observó que el belimumab es útil en pacientes colombianos con LES que son refractarios a la terapia estándar, especialmente en manifestaciones articulares, hematológicas y cutáneas, en un entorno de pacientes de la vida real.

Palabras clave:
Belimumab
Lupus eritematoso sistémico
Colombia

Article

These are the options to access the full texts of the publication Revista Colombiana de Reumatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail